Disease state overview

SH-110 capsules are the standard of care for the treatment of Glioma:

  • 12,731 adult patients in the US are diagnosed per year1
  • 2,021 pediatric patients in the US are diagnosed per year1
  • Glioma is an orphan disease

Regulatory Status

Shorla Oncology have completed a successful pre-IND meeting with the US Health Authority, the Food and Drug Administration (‘FDA’) on our third oncology drug SH-110. This proprietary product will have a significant benefit to patients suffering from brain cancer ultimately reducing treatment burden and providing a palatable age appropriate treatment. With this positive outcome we will progress our development programme for this much needed drug.

1National Brain Tumor Society Facts.